A recent study, featured in the “Journal of Neuroscience Research,” has shed light on the enhanced emotional understanding observed in regular cannabis users. The study, conducted by a team of neurobiologists at the National Autonomous University of Mexico, underscores the potential positive impact of cannabis on interpersonal relationships and its plausible therapeutic applications.
The research involved a comparison of empathy measurements between two distinct groups: 85 regular marijuana users and 51 individuals who abstained from cannabis use. The researchers utilized a 33-item written test and MRI images to gauge the participants’ empathic responses.
The written test, designed to evaluate both cognitive and affective empathy, delved into specific areas, or subscales, including the ability to empathize by placing oneself in another’s shoes and recognizing others’ impressions and emotions. Additionally, it gauged the capacity to resonate with positive and negative emotions.
The authors found that marijuana users exhibited higher scores on emotional comprehension scales, emphasizing their proficiency in recognizing and understanding others’ emotions. However, distinctions in empathy subscales beyond emotional comprehension did not reach statistical significance.
Researchers posited a potential link between cannabis use and heightened empathy, though they urged caution, emphasizing the necessity for further research to unravel the complexities involved. In their attempt to elucidate the findings, the authors highlighted the anterior cingulate cortex (ACC) as a susceptible region to cannabis effects and a key player in the complex process of empathy. The study proposed that the differences in emotional comprehension scores and brain functional connectivity observed in regular marijuana users might be linked to the impact of marijuana on the ACC, an area rich in CB1 receptors crucial for representing others’ affective states.
Despite these insights, the authors acknowledged certain limitations. Notably, they couldn’t rule out preexisting differences before marijuana-use initiation, emphasizing the study’s inability to establish causation. Moreover, empathy assessments relied on self-reported responses, lacking biochemical markers alongside subjective reports.
Additionally, the study recognized a potential disparity in THC potency between Mexican and U.S. cannabis, with the former containing lower THC levels. They noted that Mexican marijuana contained approximately 2% to 20% THC on the illegal market, potentially influencing brain outcomes differently than in studies reporting emotional dysfunctions in cannabis users.
Despite these caveats, the authors asserted that the results pave the way for further investigation into the clinical applications of cannabis in affecting mood and social interactions. The findings of such studies could end up giving major industry players such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) ideas on how they can tweak their products and appeal to consumers with specific needs.
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
CannabisNewsWire is powered by IBN